You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
信达生物(01801.HK)续升7%曾见38.75元新高 肺癌新药销情理想获瑞信升价
阿思达克 04-24 14:44
信达生物制药(01801.HK)治疗肺癌新适应症之新药信迪利单抗注射液上市申请获受理及该药首季销情较瑞信预测高30%,该股承昨天重越10天线势,今天曾进一步突破2月所创上市高位37.9元,最高见38.75元,现造37.3元,续升7%,成交已达525万股,涉资1.95亿元。

信达公布,集团与礼来制药共同开发治疗肺癌新适应症之新药「信迪利单抗注射液」上市申请已正式获国家药品监督管理局受理。该药物首季销售收入约4亿人民币,瑞信指金额较该行预测高约30%,加上该药已纳入国家医保後会有更佳医院取用及降价後更能负担等原因,料该药在今年余下时间销售会增加,故将该药全年销售预测由原先15.1亿元升至19.6亿元人民币。同时。调高信达生物今明两年收入预测33%及15%,以及其目标价由38元,升至41.5元,重申「跑赢大市」评级。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account